Review of phase I study of NC-6004, a cisplatin-incorporated polymeric micelle, in United Kingdom

DOI Web Site 26 References

Bibliographic Information

Other Title
  • 臨床開発中のＤＤＳ製剤　　シスプラチン内包ミセルＮＣ‐６００４のイギリスでの臨床第Ｉ相試験を行って
  • シスプラチン内包ミセルNC-6004のイギリスでの臨床第1相試験を行って
  • シスプラチン ナイホウ ミセル NC 6004 ノ イギリス デノ リンショウ ダイ1ソウ シケン オ オコナッテ

Search this article

Description

Clinical application of anti-tumor polymeric micellar drugs consisted with nanoparticles is on going. NC-6004 is cisplatin-incorporated micellar drug. The particle size of NC-6004 is small, which is approximately 30 nm. The particles are retained in blood flow a long time and sustain release of cisplatin. In terms of these characteristics, NC-6004 is expected to reduce the renal toxicity that is considered as one of the clinical issues of cisplatin therapy. NC-6004 is also expected to facilitate accumulation of cisplatin into tumor tissues by getting through pores in blood vessels of tumor tissues.<BR>Phase I study of NC-6004 in patients with advanced cancer was conducted in UK. The results for the study were reviewed.

Journal

  • Drug Delivery System

    Drug Delivery System 24 (1), 45-53, 2009

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(26)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top